Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
21.29
-1.12 (-5.00%)
At close: Feb 21, 2025, 4:00 PM
21.01
-0.28 (-1.32%)
After-hours: Feb 21, 2025, 7:32 PM EST
Spyre Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | - | 0.89 | 2.33 | 18.74 | - | - | |
| Revenue Growth (YoY) | - | -61.96% | -87.57% | - | - | - | |
| Cost of Revenue | 84.05 | 84.05 | 58.58 | 57.07 | 59.64 | 64.6 | |
| Gross Profit | -84.05 | -83.16 | -56.25 | -38.33 | -59.64 | -64.6 | |
| Selling, General & Admin | 49.08 | 34.45 | 28.53 | 27.32 | 21.84 | 15.73 | |
| Research & Development | 61.95 | - | - | - | - | - | |
| Operating Expenses | 111.02 | 34.45 | 28.53 | 27.32 | 21.84 | 15.73 | |
| Operating Income | -195.07 | -117.61 | -84.78 | -65.65 | -81.48 | -80.33 | |
| Interest & Investment Income | 19.66 | 6.15 | 0.84 | 0.11 | 0.59 | 2.14 | |
| Other Non Operating Income (Expenses) | -41.29 | -102.66 | -0.01 | -0.12 | -0.01 | -0.06 | |
| EBT Excluding Unusual Items | -216.69 | -214.13 | -83.95 | -65.66 | -80.89 | -78.25 | |
| Merger & Restructuring Charges | - | -10.95 | - | - | - | - | |
| Gain (Loss) on Sale of Assets | 1.84 | 16.45 | - | - | - | - | |
| Pretax Income | -214.85 | -338.82 | -83.95 | -65.66 | -80.89 | -78.25 | |
| Income Tax Expense | 0.05 | -0.03 | -0.14 | 0.14 | - | - | |
| Net Income | -214.9 | -338.79 | -83.82 | -65.8 | -80.89 | -78.25 | |
| Net Income to Common | -214.9 | -338.79 | -83.82 | -65.8 | -80.89 | -78.25 | |
| Shares Outstanding (Basic) | 37 | 7 | 3 | 3 | 2 | 1 | |
| Shares Outstanding (Diluted) | 37 | 7 | 3 | 3 | 2 | 1 | |
| Shares Change (YoY) | 845.79% | 104.59% | 28.19% | 23.18% | 67.05% | 53.44% | |
| EPS (Basic) | -5.79 | -49.12 | -24.86 | -25.02 | -37.89 | -61.23 | |
| EPS (Diluted) | -5.79 | -49.12 | -24.86 | -25.02 | -37.89 | -61.23 | |
| Free Cash Flow | -151.25 | -99.91 | -80.18 | -54.29 | -80.06 | -67.18 | |
| Free Cash Flow Per Share | -4.07 | -14.49 | -23.78 | -20.64 | -37.50 | -52.57 | |
| Gross Margin | - | - | - | -204.55% | - | - | |
| Operating Margin | - | -13274.49% | -3640.23% | -350.33% | - | - | |
| Profit Margin | - | -38238.15% | -3598.75% | -351.14% | - | - | |
| Free Cash Flow Margin | - | -11276.52% | -3442.77% | -289.71% | - | - | |
| EBITDA | -194.51 | -116.87 | -83.21 | -64.07 | -80.49 | -79.92 | |
| D&A For EBITDA | 0.56 | 0.74 | 1.57 | 1.58 | 1 | 0.42 | |
| EBIT | -195.07 | -117.61 | -84.78 | -65.65 | -81.48 | -80.33 | |
| Revenue as Reported | - | 0.89 | 2.33 | 18.74 | - | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.